UCB SA (LON:0NZT)

London flag London · Delayed Price · Currency is GBP · Price in EUR
239.85
-4.47 (-1.83%)
At close: Dec 4, 2025
27.59%
Market Cap 41.06B
Revenue (ttm) 5.87B
Net Income (ttm) 1.14B
Shares Out n/a
EPS (ttm) 5.89
PE Ratio 35.96
Forward PE 27.52
Dividend 0.83 (0.35%)
Ex-Dividend Date Apr 25, 2025
Volume 13,275
Average Volume 95,014
Open 237.75
Previous Close 244.32
Day's Range 237.50 - 241.40
52-Week Range 129.35 - 263.20
Beta 0.22
RSI 62.49
Earnings Date Feb 26, 2026

About UCB SA

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company’s primary products include Cimzia for inflammatory TNF-mediated diseases, as well as ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson’s disease and restless legs syndrome. It also provides Nayzilam, a nasal spra... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1925
Employees 9,378
Stock Exchange London Stock Exchange
Ticker Symbol 0NZT
Full Company Profile

Financial Performance

In 2024, UCB SA's revenue was 6.15 billion, an increase of 18.72% compared to the previous year's 5.18 billion. Earnings were 1.07 billion, an increase of 210.50%.

Financial numbers in EUR Financial Statements

News

There is no news available yet.